vs

Side-by-side financial comparison of Lamb Weston (LW) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

Lamb Weston is the larger business by last-quarter revenue ($1.6B vs $961.0M, roughly 1.6× DENTSPLY SIRONA Inc.). Lamb Weston runs the higher net margin — 3.5% vs -15.2%, a 18.6% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs 2.9%). DENTSPLY SIRONA Inc. produced more free cash flow last quarter ($60.0M vs $-36.3M). Over the past eight quarters, DENTSPLY SIRONA Inc.'s revenue compounded faster (0.4% CAGR vs -1.5%).

Lamb Weston Holdings, Inc. is an American food processing company that is one of the world's largest producers and processors of frozen french fries, waffle fries, and other frozen potato products. It is headquartered in Eagle, Idaho, a suburb of Boise.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

LW vs XRAY — Head-to-Head

Bigger by revenue
LW
LW
1.6× larger
LW
$1.6B
$961.0M
XRAY
Growing faster (revenue YoY)
XRAY
XRAY
+3.3% gap
XRAY
6.2%
2.9%
LW
Higher net margin
LW
LW
18.6% more per $
LW
3.5%
-15.2%
XRAY
More free cash flow
XRAY
XRAY
$96.3M more FCF
XRAY
$60.0M
$-36.3M
LW
Faster 2-yr revenue CAGR
XRAY
XRAY
Annualised
XRAY
0.4%
-1.5%
LW

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
LW
LW
XRAY
XRAY
Revenue
$1.6B
$961.0M
Net Profit
$54.0M
$-146.0M
Gross Margin
21.2%
46.1%
Operating Margin
8.1%
-14.5%
Net Margin
3.5%
-15.2%
Revenue YoY
2.9%
6.2%
Net Profit YoY
-63.0%
66.0%
EPS (diluted)
$0.39
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LW
LW
XRAY
XRAY
Q1 26
$1.6B
Q4 25
$1.6B
$961.0M
Q3 25
$1.7B
$904.0M
Q2 25
$1.7B
$936.0M
Q1 25
$1.5B
$879.0M
Q4 24
$1.6B
$905.0M
Q3 24
$1.7B
$951.0M
Q2 24
$1.6B
$984.0M
Net Profit
LW
LW
XRAY
XRAY
Q1 26
$54.0M
Q4 25
$62.1M
$-146.0M
Q3 25
$64.3M
$-427.0M
Q2 25
$119.9M
$-45.0M
Q1 25
$146.0M
$20.0M
Q4 24
$-36.1M
$-430.0M
Q3 24
$127.4M
$-494.0M
Q2 24
$129.6M
$-4.0M
Gross Margin
LW
LW
XRAY
XRAY
Q1 26
21.2%
Q4 25
20.0%
46.1%
Q3 25
20.6%
48.8%
Q2 25
20.4%
52.4%
Q1 25
27.8%
53.0%
Q4 24
17.4%
49.3%
Q3 24
21.5%
52.1%
Q2 24
24.1%
51.9%
Operating Margin
LW
LW
XRAY
XRAY
Q1 26
8.1%
Q4 25
8.6%
-14.5%
Q3 25
9.4%
-24.1%
Q2 25
11.1%
-13.7%
Q1 25
16.4%
7.2%
Q4 24
1.2%
-56.2%
Q3 24
12.8%
-48.6%
Q2 24
13.2%
5.1%
Net Margin
LW
LW
XRAY
XRAY
Q1 26
3.5%
Q4 25
3.8%
-15.2%
Q3 25
3.9%
-47.2%
Q2 25
7.2%
-4.8%
Q1 25
9.6%
2.3%
Q4 24
-2.3%
-47.5%
Q3 24
7.7%
-51.9%
Q2 24
8.0%
-0.4%
EPS (diluted)
LW
LW
XRAY
XRAY
Q1 26
$0.39
Q4 25
$0.44
$-0.74
Q3 25
$0.46
$-2.14
Q2 25
$0.84
$-0.22
Q1 25
$1.03
$0.10
Q4 24
$-0.25
$-2.09
Q3 24
$0.88
$-2.46
Q2 24
$0.89
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LW
LW
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$57.5M
$326.0M
Total DebtLower is stronger
$3.6B
$2.3B
Stockholders' EquityBook value
$1.8B
$1.3B
Total Assets
$7.4B
$5.4B
Debt / EquityLower = less leverage
1.99×
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LW
LW
XRAY
XRAY
Q1 26
$57.5M
Q4 25
$82.7M
$326.0M
Q3 25
$98.6M
$363.0M
Q2 25
$70.7M
$359.0M
Q1 25
$67.5M
$398.0M
Q4 24
$79.0M
$272.0M
Q3 24
$120.8M
$296.0M
Q2 24
$71.4M
$279.0M
Total Debt
LW
LW
XRAY
XRAY
Q1 26
$3.6B
Q4 25
$3.6B
$2.3B
Q3 25
$3.7B
Q2 25
$3.7B
Q1 25
$3.7B
Q4 24
$3.7B
$1.7B
Q3 24
$3.4B
Q2 24
$3.4B
Stockholders' Equity
LW
LW
XRAY
XRAY
Q1 26
$1.8B
Q4 25
$1.8B
$1.3B
Q3 25
$1.8B
$1.5B
Q2 25
$1.7B
$2.0B
Q1 25
$1.6B
$2.0B
Q4 24
$1.6B
$1.9B
Q3 24
$1.8B
$2.5B
Q2 24
$1.8B
$3.1B
Total Assets
LW
LW
XRAY
XRAY
Q1 26
$7.4B
Q4 25
$7.3B
$5.4B
Q3 25
$7.2B
$5.7B
Q2 25
$7.4B
$6.1B
Q1 25
$7.4B
$6.0B
Q4 24
$7.5B
$5.8B
Q3 24
$7.5B
$6.6B
Q2 24
$7.4B
$6.9B
Debt / Equity
LW
LW
XRAY
XRAY
Q1 26
1.99×
Q4 25
2.08×
1.70×
Q3 25
2.05×
Q2 25
2.12×
Q1 25
2.25×
Q4 24
2.26×
0.90×
Q3 24
1.87×
Q2 24
1.92×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LW
LW
XRAY
XRAY
Operating Cash FlowLast quarter
$65.2M
$101.0M
Free Cash FlowOCF − Capex
$-36.3M
$60.0M
FCF MarginFCF / Revenue
-2.3%
6.2%
Capex IntensityCapex / Revenue
6.5%
4.3%
Cash ConversionOCF / Net Profit
1.21×
TTM Free Cash FlowTrailing 4 quarters
$569.2M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LW
LW
XRAY
XRAY
Q1 26
$65.2M
Q4 25
$178.4M
$101.0M
Q3 25
$352.0M
$79.0M
Q2 25
$868.3M
$48.0M
Q1 25
$56.0M
$7.0M
Q4 24
$99.1M
$87.0M
Q3 24
$330.2M
$141.0M
Q2 24
$798.2M
$208.0M
Free Cash Flow
LW
LW
XRAY
XRAY
Q1 26
$-36.3M
Q4 25
$101.0M
$60.0M
Q3 25
$274.4M
$40.0M
Q2 25
$230.1M
$16.0M
Q1 25
$-19.8M
$-12.0M
Q4 24
$-49.6M
$36.0M
Q3 24
$4.3M
$98.0M
Q2 24
$-131.3M
$156.0M
FCF Margin
LW
LW
XRAY
XRAY
Q1 26
-2.3%
Q4 25
6.2%
6.2%
Q3 25
16.5%
4.4%
Q2 25
13.7%
1.7%
Q1 25
-1.3%
-1.4%
Q4 24
-3.1%
4.0%
Q3 24
0.3%
10.3%
Q2 24
-8.1%
15.9%
Capex Intensity
LW
LW
XRAY
XRAY
Q1 26
6.5%
Q4 25
4.8%
4.3%
Q3 25
4.7%
4.3%
Q2 25
38.1%
3.4%
Q1 25
5.0%
2.2%
Q4 24
9.3%
5.6%
Q3 24
19.7%
4.5%
Q2 24
57.7%
5.3%
Cash Conversion
LW
LW
XRAY
XRAY
Q1 26
1.21×
Q4 25
2.87×
Q3 25
5.47×
Q2 25
7.24×
Q1 25
0.38×
0.35×
Q4 24
Q3 24
2.59×
Q2 24
6.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LW
LW

Segments North America$1.0B66%
Segments International$529.8M34%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons